NICE recommends Bravtovi + Mektovi combination in melanoma.- Pierre Fabre + Array Biopharma
The UK National Institute for Health and Care Excellence (NICE) has recommended Bravtovi (encorafenib) plus Mektovi (binimetinib) from Pierre Fabre + Array Biopharma, as an option for adults with BRAF V600 mutation-positive melanoma, that cannot be removed surgically or that has spread to nearby organs.
Comment: Braftovi + Mektovi is the first targeted treatment to achieve over 30 months median overall survival (OS). As published in The Lancet Oncology in September 2018, Braftovi + Mektovi reduced the risk of death compared to vemurafenib. Median OS was 33.6 months for patients treated with the combination, compared to 16.9 months for patients treated with vemurafenib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.